Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
The master cytokine TGF-β mediates tissue fibrosis associated with inflammation and tissue injury. TGF-β induces fibroblast activation and differentiation into myofibroblasts that secrete extracellular matrix proteins. Canonical TGF-β signaling mobilizes Smad2 and Smad3 transcription factors that control fibrosis by promoting gene expression. However, the importance of TGF-β-Smad2/3 signaling in fibroblast-mediated cardiac fibrosis has not been directly evaluated in vivo. Here, we examined pressure overload-induced cardiac fibrosis in fibroblast- and myofibroblast-specific inducible Cre-expressing mouse lines with selective deletion of the TGF-β receptors Tgfbr1/2, Smad2, or Smad3. Fibroblast-specific deletion of Tgfbr1/2 or Smad3, but not Smad2, markedly reduced the pressure overload-induced fibrotic response as well as fibrosis mediated by a heart-specific, latency-resistant TGF-β mutant transgene. Interestingly, cardiac fibroblast-specific deletion of Tgfbr1/2, but not Smad2/3, attenuated the cardiac hypertrophic response to pressure overload stimulation. Mechanistically, loss of Smad2/3 from tissue-resident fibroblasts attenuated injury-induced cellular expansion within the heart and the expression of fibrosis-mediating genes. Deletion of Smad2/3 or Tgfbr1/2 from cardiac fibroblasts similarly inhibited the gene program for fibrosis and extracellular matrix remodeling, although deletion of Tgfbr1/2 uniquely altered expression of an array of regulatory genes involved in cardiomyocyte homeostasis and disease compensation. These findings implicate TGF-β-Smad2/3 signaling in activated tissue-resident cardiac fibroblasts as principal mediators of the fibrotic response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overexpression of SMAD3 enhances, whereas knockdown inhibits αSMA and extracellular matrix production in fibroblasts (45–48). Furthermore, fibroblast-specific deletion of SMAD3 reduces αSMA production and myofibroblast phenotype (49–52), for example, loss of SMAD3 lowers the number of activated myofibroblasts in cardiac fibrosis in vivo and reduces extracellular matrix production by myofibroblasts”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [47]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“By contrast, cultured human primary cardiac and dermal fibroblasts and immortalized cardiac fibroblasts were relatively poor models of human cardiac fibroblast diversity under resting or stimulated (TGFβ (refs. 19,39,40), IL-1β (ref. 41)) conditions.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“TGF-β1 activates SMAD2/3 signaling, driving pro-fibrotic gene expression and extracellular matrix deposition in cardiac fibroblasts [85].”
From A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease (2026) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, primary human cardiac fibroblasts, primary human dermal fibroblasts, and immortalized human cardiac fibroblasts were relatively poor models of human cardiac fibroblast diversity under resting or stimulated (TGFβ 20,33,34 , IL-1 β 35 ) conditions.”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“While numerous studies have implicated a role for TGFβ signaling in maladaptive cardiac remodeling and scar formation in HF 20,33”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [33]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591 · cited 1×
“Heart failure is an increasingly prevalent disease characterized by reduced cardiac output resulting from a progressive loss of cardiomyocytes, ventricular chamber remodeling, and accumulation of interstitial fibrosis (1).”
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F., Dokainish, H., Edvardsen, T., Flachskampf, F. A., Gillebert, T. C., Klein, A. L., Lancellotti, P., et al. (2016) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2016.01.011 · Cited by 5,262
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528 · cited 1×
“Global TGF-β activity is upregulated in diseased hearts, where one of its primary actions is directed at the resident fibroblasts to alter the fibrotic response and ventricular remodeling (47, 48).”
Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F., Dokainish, H., Edvardsen, T., Flachskampf, F. A., Gillebert, T. C., Klein, A. L., Lancellotti, P., et al. (2016) · European Heart Journal – Cardiovascular Imaging · doi:10.1093/ehjci/jew082 · Cited by 2,425 · cited 1×
“The ratio of these measures ( E/e ′ ) was used as an indicator of diastolic function (60).”
Cardiac Fibroblast: The Renaissance Cell
Souders, C. A., Bowers, S. L. K., & Baudino, T. A. (2009) · Circulation Research · doi:10.1161/circresaha.109.209809 · Cited by 984 · cited 1×
“Progressive cardiac fibrosis in heart failure is predominantly mediated by the tissue-resident cardiac fibroblast, which becomes activated and then differentiated into a cell type referred to as the myofibroblast (5, 6).”
Transforming growth factor (TGF)-β signaling in cardiac remodeling
Dobaczewski, M., Chen, W., & Frangogiannis, N. G. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.033 · Cited by 934 · cited 1×
“TGF-β is considered a “master” cytokine/growth factor produced within injured or diseased tissues, where it activates fibroblasts and facilitates ECM production (15, 16).”
The role of TGF-β signaling in myocardial infarction and cardiac remodeling
BUJAK, M., & FRANGOGIANNIS, N. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.10.002 · Cited by 927
Genetic lineage tracing defines myofibroblast origin and function in the injured heart
Kanisicak, O., Khalil, H., Ivey, M. J., Karch, J., Maliken, B. D., Correll, R. N., Brody, M. J., J. Lin, S.-C., Aronow, B. J., Tallquist, M. D., et al. (2016) · Nature Communications · doi:10.1038/ncomms12260 · Cited by 892 · cited 6×
“Hence, here we used mice in which the Postn genetic locus was targeted with a tamoxifen-inducible MerCreMer (MCM) cDNA (29), and these mice were crossed with Smad2 fl/fl , Smad3 fl/fl , Smad2/3 fl/fl , and Tgfbr1/2 fl/fl targeted mice (Figure 2A).”
InfluentialSelf-citation
Cited by
Items 601–700 of 925
Transcriptional plasticity of fibroblasts in heart disease
Micheletti, R., & Alexanian, M. (2022) · Biochemical Society Transactions · doi:10.1042/bst20210864 · Cited by 7
Han, Z., Zhang, X., Lu, M., Lu, M., Wang, J., Nie, Y., & Zhang, H. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.04.019 · Cited by 7
Promising Therapeutic Treatments for Cardiac Fibrosis: Herbal Plants and Their Extracts
Yu, X. (2023) · Cardiology and Therapy · doi:10.1007/s40119-023-00319-4 · Cited by 8
Fu, R., You, N., Li, R., Zhao, X., Li, Y., Li, X., & Jiang, W. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003635 · Cited by 7
The zinc-finger transcription factor KLF6 regulates cardiac fibrosis
Li, N., Xue, Y., Zhu, C., Chen, N., Qi, M., Fang, M., & Huang, S. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122805 · Cited by 8
Therapeutic effect of Momordica charantia on cardiomyopathy in a diabetic maternal rat model
Elnahas, S. M., Mansour, H. A. E., El-Sawi, M. R., & Abou‐El‐Naga, A. M. (2024) · Journal of Experimental Zoology Part A Ecological and Integrative Physiology · doi:10.1002/jez.2854 · Cited by 7
A Flowable Placental Formulation Prevents Bleomycin-Induced Dermal Fibrosis in Aged Mice
Dhall, S., Lerch, A., Johnson, N., Jacob, V., Jones, B., Park, M. S., & Sathyamoorthy, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124242 · Cited by 7
“The reduced number of pSmad2-positive cells in FPF-treated skin samples, in comparison to untreated control, is a strong indication of reduced transcriptional modulation by TGF-β [48].”
BackgroundResearch Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases
Jia, M.-Q., Guan, C., Tao, J., & Zhou, Y. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5042762 · Cited by 8
Li, Y., Chen, S., Tan, J., Zhou, Y., Ren, M., Zhang, Q., Zhao, M., Yuan, G., Zhang, W., & Yang, F. (2023) · Renal Failure · doi:10.1080/0886022x.2022.2120821 · Cited by 7
“SM934 treatment downregulated the expressions of TGF-b and Smad2/3 by reducing macrophage infiltration, and ultimately reduced the number of myofibroblasts and the expression of collagen.”
BackgroundKnockdown of HIPK2 Attenuates Angiotensin II–Induced Cardiac Fibrosis in Cardiac Fibroblasts
Xu, F., Mao, B., Li, Y., & Zhao, Y. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001292 · Cited by 7
Defining Cardiac Recovery at Single Cell Resolution
Amrute, J. M., Lai, L., Ma, P., Koenig, A. L., Kamimoto, K., Bredemeyer, A., Shankar, T. S., Kuppe, C., Kadyrov, F. F., Schulte, L. J., et al. (2022) · doi:10.1101/2022.09.11.507463 · Cited by 6
Sex differences in aortic valve inflammation and remodeling in chronic severe aortic regurgitation
Tiraplegui, C., Garaikoetxea, M., Sádaba, A., Ildefonso-García, S. S., Goñi-Olóriz, M., Fernández‐Celis, A., Martín‐Núñez, E., Álvarez, V., Sádaba, R., Anand, V., et al. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00645.2024 · Cited by 7
Demystifying the diagnosis and management of ICUS, CHIP, and CCUS
Xie, Z., Lee, D. H., Hansen, D. K., & Loghavi, S. (2025) · Hematology · doi:10.1182/hematology.2025000766 · Cited by 6
Immunometabolism in Cardiac Remodeling: Mechanisms and Therapeutic Perspectives
Nazaruk, J., Bilnik, B., Niewiadomski, M., Pawlak, W., & Gajewski, P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093906 · Cited by 8
“Persistent activation of this pathway contributes to myocardial stiffening and structural remodeling, making it an attractive therapeutic target in fibrotic heart disease [82,101].”
Cardiomyocyte-expressed TGFβ programs early heart maturation and adult myocyte identity
Minerath, R. A., Kasam, R. K., Swoboda, C. O., Prasad, V., Grimes, K. M., Blair, N. S., Khalil, H., Alfieri, C. M., Eads, L., Saviola, A. J., et al. (2026) · Nature Cardiovascular Research · doi:10.1038/s44161-026-00892-6 · Cited by 6
Self-citationKawaguchi, S., Sepúlveda, M., Teoh, J., Hayasaka, T., Moukette, B. M., Aonuma, T., Roh, H. C., Madhur, M. S., & Kim, I. (2024) · Biomolecules · doi:10.3390/biom14121650 · Cited by 6
He, Y., Dai, M., Tao, L., Gu, X., Wang, H., & Liu, P. (2025) · The Journal of Gene Medicine · doi:10.1002/jgm.70003 · Cited by 6
“Deletion of TGF-β1 or Smad3 from mouse activated fibroblasts could attenuate the degree of cardiac fibrosis due to pressure overload [27,28].”
Lin, Z., Yu, Q., Yi, B., Xu, W., He, H., Huang, K., Zheng, C., Wu, S., & Lin, J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037402 · Cited by 6
“36 Other studies have indicated that Cav-1 is involved in the regulation of ion channels, which results in alterations to cardiac electrical function.”
Artemisinin and Its Derivatives: Promising Therapeutic Agents for Age-Related Macular Degeneration
Liu, C., Liu, X., & Duan, J. (2025) · Pharmaceuticals · doi:10.3390/ph18040535 · Cited by 6
“The resulting Smad2/3-Smad4 complex translocates to the SBEs on profibrotic gene promoters [123,124].”
Cheng, X., Zhang, Y., Guo, H., Li, X., Wang, Y., Song, Y., Wang, H., & Ma, D. (2023) · Food Science & Nutrition · doi:10.1002/fsn3.3758 · Cited by 6
Luo, C., Tan, B., Chu, L., Chen, L., Zhong, X., Jiang, Y., Yan, Y., Mo, F., Wang, H., & Yang, F. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1460813 · Cited by 6
New insights into Smad3 in cardiac fibrosis
Gao, Z. (2025) · Gene · doi:10.1016/j.gene.2025.149418 · Cited by 7
Fadeeva, M. V., Схиртладзе, М. Р., & Ivashkin, V. T. (2019) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2019-29-3-38-48 · Cited by 7
Nemir, M., Kay, M., Maison, D., Berthonneche, C., Sarre, A., Plaisance, I., & Pedrazzini, T. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9040111 · Cited by 6
Zeng, N., Jian, Z., Xu, J., Zheng, S., Fan, Y., & Xiao, F. (2023) · Journal of Molecular Histology · doi:10.1007/s10735-023-10161-6 · Cited by 7
“Deletion of Smad2/3 from cardiac fibroblasts may also hinder fibrosis and ECM remodeling (Khalil et al. 2017).”
BackgroundPan, D., Yang, F., Zhu, S., Li, Y., Ning, G., & Feng, S. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00705-8 · Cited by 6
RetractedWikan, N., Potikanond, S., & Nimlamool, W. (2022) · Cells · doi:10.3390/cells11172731 · Cited by 7
Almusallam, N., Alonazi, A. S., Dayel, A. F. B., Almubarak, A., Ali, R., Althakfi, W., Ali, R., & Al-Rasheed, N. M. (2024) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2024.102102 · Cited by 5
“TGF-β 1 has been established as a profibrotic cytokine that negotiates tissue fibrosis incorporated with inflammation and tissue injury in post-MI remodelling (Khalil et al., 2017).”
BackgroundJiang, F., Tang, J., Wei, X., Pan, H., Fan, X., Zhang, P., & Guo, S. (2025) · Chinese Medicine · doi:10.1186/s13020-025-01062-9 · Cited by 5
Radiation-Induced Cardiac Remodeling: Mechanisms and Therapeutic Approaches
Ghnim, Z. S., Adhab, A. H., Mahdi, M. S., Kyada, A., Roopashree, R., Thakur, V., Kaur, M., Gupta, A., Mansoor, A. S., Radi, U. K., et al. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-025-10006-6 · Cited by 6
“These pathways promote the transcription of genes involved in ECM production, such as collagen and fibronectin [135, 136].”
Bio-based nanomaterials for targeted drug delivery in myocardial fibrosis
Jiang, Y., Zhou, Y., Li, Z., & Guo, L. (2025) · Industrial Crops and Products · doi:10.1016/j.indcrop.2025.121340 · Cited by 6
Kuna, J., Chmielewski, G., Jaśkiewicz, Ł., Knapik, M., & Krajewska–Włodarczyk, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178194 · Cited by 5
“The activation of heart fibroblasts is triggered by TGF-beta1, and their transformation into myofibroblasts by the activation of Smad 2/3 (classical Smad pathway) [105].”
Li, J., Tang, Y., Chen, P., Ding, Z., & Zhou, M. (2025) · Radiation Medicine and Protection · doi:10.1016/j.radmp.2025.09.005 · Cited by 5
Yuan, S., Zhu, W., Wang, Y., & Yu, L. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s539571 · Cited by 6
Sakata, K., Pinto, C. Y. A., Ali, S. Y., Loeffler, S., Prakosa, A., Tice, B. M., Kholmovski, E. G., Marine, J. E., Calkins, H. G., SPRAGG, D. D., et al. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.10.052 · Cited by 5
Amirrad, F., Fishbein, G. A., Edwards, R. A., & Nauli, S. M. (2022) · Cell and Tissue Research · doi:10.1007/s00441-022-03704-y · Cited by 6
“Smad3 has a critical role in the fibroblast activation and cardiac fibrosis in response to the TGF-β 1 or pressure overload (Khalil, et al., 2017).”
He, C., Gu, L., Li, A., Li, Y., Xiao, R., Liao, J., Mu, J., Gan, Y., Peng, M., Mohan, G., et al. (2023) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2023.101947 · Cited by 5
Inducible Fgf13 ablation alleviates cardiac fibrosis via regulation of microtubule stability
Wang, C., Wang, X., Zhang, Y., Mi, Y., Han, Y., Zhi, Y., Zhao, R., Cui, N., Ma, Q., Zhang, H., et al. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024075 · Cited by 10
Mondal, A., Das, S., Das, M., Chakraborty, S., & Sengupta, A. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130666 · Cited by 5
Jia, Q., Ding, Y., Su, Z., Chen, H., Ye, J., Xie, D., Wu, Y., He, H., Peng, Y., & Ni, Y. (2024) · Biofabrication · doi:10.1088/1758-5090/ad9cc4 · Cited by 5
“The transition of fibroblast into myofibroblast is vastly activated by different signaling pathways, such as the transforming growth factor-β (TGF-β ) pathway [8], the epithelial-mesenchymal transition [9], and the Notch signaling pathway [10].”
Ling, C., Yin, Y., Li, J., Li, J., Zhu, Z., & Li, J. (2024) · Burns · doi:10.1016/j.burns.2024.107353 · Cited by 5
TFAP4 exacerbates pathological cardiac fibrosis by modulating mechanotransduction
Liu, J., Feng, J., Zhao, J., Kong, X., Yu, Z., Huang, Y., He, Z., Liu, M., Liu, Z., Lu, Z., et al. (2025) · Cell Insight · doi:10.1016/j.cellin.2025.100256 · Cited by 6
“While the transcription factors (TFs) downstream of mechano-transduction such as YAP/TAZ(Mia et al., 2022) and SMADs(Khalil et al., 2017) are well documented, the TFs that govern the expression of mechanotransduction pathways remain poorly understood.”
Wang, T., Lan, Q., Deng, H., Han, W., Zhang, R., & Zhong, J. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1570008 · Cited by 6
Transcriptional profiles of genes related to electrophysiological function in Scn5a+/− murine hearts
Takla, M., Edling, C. E., Zhang, K., Saadeh, K., Tse, G., Salvage, S. C., Huang, C. L.-H., & Jeevaratnam, K. (2021) · Physiological Reports · doi:10.14814/phy2.15043 · Cited by 6
“The resulting deposition of types I (Col1a1) and III (Col3a1) collagen fibrils creates scar tissue (Khalil et al., 2017).”
BackgroundDedifferentiation of Human Cardiac Myofibroblasts Is Independent of Activation of COX-2/PGE2 Pathway
Luu, V. T., Phan, S., & Jin, Z.-Q. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063023 · Cited by 5
“Accumulating evidence indicates that myofibroblasts have capacity for dedifferentiation, a process which is defined as the loss of α-SMA, the hallmark for myofibroblasts [9].”
BackgroundInfluentialLiterature Review: Pathophysiology of Heart Failure with Preserved Ejection Fraction
Ahmed, F., Kahlon, T., Mohamed, T., Ghafghazi, S., & Settles, D. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101745 · Cited by 5
Hong, M. H., Jang, Y. J., Yoon, J. J., Lee, H. S., Kim, H. Y., & Kang, D. G. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116844 · Cited by 5
Is MG53 a potential therapeutic target for cancer?
Du, Y., Li, T., & Yi, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1295349 · Cited by 5
Hu, Y., Zhou, C., Zhong, Q., Li, X., Li, J., Shi, Y., Ma, X., Jiang, D., Wang, Y., Zhuang, S., et al. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2392849 · Cited by 5
“based on the aforementioned results in the study, we further explore the molecular mechanisms of LCZ696 in tGF-β1-induced HPMCs. regarding the crucial role of tGF-β/Smad3 signaling pathway on the progression of PF [6], we thus evaluated the effect of LCZ696 on this signaling pathway.”
BackgroundWang, H., Chen, Y.-H., Chen, Y., Huang, W. J., Zhu, X., Ni, F., Wu, G.-D., Xu, Z., Huang, Z., Chen, B., et al. (2018) · Europe PMC (PubMed Central) · Cited by 7
Li, W., Liao, H.-H., Feng, H., Zhou, Z., Mou, S.-Q., Zhang, N., Wu, H., Xia, H., & Tang, Q. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.04.001 · Cited by 5
Liu, L., Zhou, X., Zhang, Q., Li, L., Shang, Y., Wang, Z., Zhong, M., Chen, Y., Zhang, W., & Tang, M. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221095049 · Cited by 5
Septin4 Regulates Cardiac Fibrosis After Pressure Overload
Yücel, D., de Araújo, N. F., Souza-Neto, F., Smith, C., Lin, W., Torniainen, A. A., Hall, M. L., Townsend, D., Ogle, B. M., & van Berlo, J. H. (2025) · Circulation Research · doi:10.1161/circresaha.125.326758 · Cited by 4
“3 6 Recent papers have shown a direct correlation between the development of cardiac fibrosis and outcome.”
TET3 is a regulator and can be targeted for the intervention of myocardial fibrosis
Zhu, C., Hong, W., Zhu, Y., Xue, Y., Fang, Z., Jiang, D., Xu, Y., & Kong, M. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00305-4 · Cited by 5
Novel angiotensin receptor target as therapy for the diabetic heart: the AT2R
Li, M., Wang, Y., & Widdop, R. E. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.11.003 · Cited by 4
Shama, A., El‐Bassiouny, N. A., Bahnacy, Y., & Werida, R. H. (2025) · Journal of Dietary Supplements · doi:10.1080/19390211.2025.2601020 · Cited by 4
“Myocardial fibrosis development and myofibroblast differentiation are both influenced by TGF-β1, the most prevalent of the three TGF-β isoforms (Khalil et al. 2017).”
Targeting Cardiac Fibroblast Plasticity for Antifibrotic and Regenerative Therapy in Heart Failure
Dutta, S., Chen, S., Ahmad, W., Huang, W. C., Liang, J., & Wang, Y. (2026) · Cells · doi:10.3390/cells15020112 · Cited by 7
Psychological stress and myocardial extracellular matrix remodeling- a pathologic synergy
Spinale, F. G., Weil, B. R., Sharma, U. C., Wood, S. K., Hollis, F., Meléndez, G. C., DeLeon‐Pennell, K. Y., Bradshaw, A. D., Lang, J. K., Canty, J. M., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117795 · Cited by 4
Mallol-Simmonds, M., Avila, C., Cañete, I., Parra-Lucares, A., Pena-Silva, J., & Bustamante, S. (2026) · Biomedicines · doi:10.3390/biomedicines14020486 · Cited by 4
“For instance, it corrected an MYH7 mutation in hypertrophic cardiomyopathy (HCM) patient-derived iPSCs, restoring 90% of cardiomyocyte contractility in vitro, as measured by calcium transients [92].”
Kozdrowicki, M., Szczepaniak, P., Kyslyi, V. F., Carnevale, L., Carnevale, D., Lembo, G., Guzik, T. J., & Mikolajczyk, T. P. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag054 · Cited by 4
Cardiac mechanotransduction from development to disease
Kim, N. Y., Jo, H., Becker, C., Soicher, I., Ni, Y., Cho, S., & Kim, H. (2026) · APL Bioengineering · doi:10.1063/5.0320788 · Cited by 6
Faust, M. N., Nguyen, A. K., Gorashi, R. M., Vélez, N. E. F., Loud, M. C., & Aguado, B. A. (2026) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-026-00923-z · Cited by 4
Myocardial Fibrosis: Cell Signaling and In Vitro Modeling
Graham, C., & Sethu, P. (2022) · Springer eBooks · doi:10.1007/978-3-031-08309-9_10 · Cited by 4
Zhang, Y., Lu, Y., Hu, X., Jiang, M., Chen, Z., Jin, L., Li, M., Chen, C., & Wang, J. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.11.019 · Cited by 4
Novel Therapeutic Strategies Targeting Fibroblasts to Improve Heart Disease
Li, Y. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31504 · Cited by 4
“However, under pathological conditions, quiescent fibroblasts undergo a transformation into myofibroblasts through interactions with TGF ‐ β and SMAD 2/3 signaling pathways (Dixon and Cunnington 2011; Khalil et al. 2017; Rurik, Aghajanian, and Epstein 2021; Schafer et al. 2017).”
Lin, P., Chen, H., Cui, Z., Yu, B., Kou, J., & Li, F. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60806-5 · Cited by 4
Jin, C., Ye, Y., Gao, L., Zhong, Z., Zhou, C., Wu, X., Li, X., Zhou, G., Chen, S., Wei, Y. Q., et al. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01408-8 · Cited by 5
Single cell transcriptional perturbome in pluripotent stem cell models
Balmas, E., Ratto, M. L., Snijders, K. E., Becca, S., Liaci, C., Ricca, I., Merlo, G. R., Calogero, R., Alessandrì, L., Mendjan, S., et al. (2025) · Molecular Systems Biology · doi:10.1038/s44320-025-00172-8 · Cited by 6
Effects of Kangdaxin on myocardial fibrosis in heart failure with preserved ejection fraction rats
Wu, X., Zhang, T., Qiao, J., Li, C., Chao, L., & Xiong, S.-Q. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-198 · Cited by 4
“In the TGF-β 1 signal pathway, Smads protein is the main effector molecule in the middle and downstream of the signal pathway, The TGF-β 1 receptor regulates the expression of related genes by phosphorylating Smad protein and promotes the development of fibrosis (9,10).”
Tao, L., Qin, Z., Lin, L., Guo, H., Liang, Z., Wang, T., Xu, J., Xu, M., Hua, F., & Su, X. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00515.2023 · Cited by 4
Hughes, T. A. G., Dona, M. S. I., Sobey, C. G., Pinto, A. R., Drummond, G. R., Vinh, A., & Jelinic, M. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.20597 · Cited by 6
“This is typically in response to cytokines which can induce further release of cytokines (including TGF-β 1, 72 IL-6, and MCP-1 73 ) to promote inflammation and fibroblast proliferation.”
BackgroundDACT2 modulates atrial fibrillation through TGF/β and Wnt signaling pathways
Luo, B., Zheng, R., Shi, C., Chen, D., Jin, X., Hou, J., Xu, G., & Hu, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36050 · Cited by 6
Kim, I. Y., Lee, H. L., Choi, H., Ju, Y., Heo, Y. M., Na, H. R., Lee, D. Y., Jeong, W. M., & Heo, H. J. (2024) · Antioxidants · doi:10.3390/antiox13121572 · Cited by 5
Zhang, J., Wang, W., Wang, Z., Zhou, M., & Wu, S.-B. (2025) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-025-03404-y · Cited by 4
“TGF-β upregulation is a hallmark of fibrotic diseases, exerting a pivotal regulatory function in FBs activation and extra-cellular matrix (ECM) production [17].”
Shi, Y., Li, J., Zhong, Q., Chen, H., Ma, X., Hu, Y., Wang, Y., Jiang, D., Zhou, X., Li, X., et al. (2025) · The Journal of Pathology · doi:10.1002/path.6436 · Cited by 4
Fu, X., Li, C., Liu, Q., & McMillin, K. (2019) · Journal of Animal Science · doi:10.1093/jas/skz111 · Cited by 4
Self-citationZhang, M., Liu, X., Wu, J., Yu, Y., Wang, Y., & Gu, Y. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00375 · Cited by 4
“Canonical TGF-β signaling promotes cardiac fibrosis by activating Smad2/3 transcription factors through upregulating gene expression (Khalil et al., 2017).”
BackgroundLi, S., Li, Z., Yin, R., Nie, J., Fu, Y., & Ying, R. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105902 · Cited by 4
Liu, J., Jin, Y., Wang, B., Zhang, J., & Zuo, S. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13212 · Cited by 5
[The potential role of long non-coding RNA Dnm3os in the activation of cardiac fibroblasts].
Kong, Q., Zhou, J., Tian, G., Quan, Y., Wu, W.-C., & Liu, X. (2021) · PubMed Central · doi:10.7507/1001-5515.202102021 · Cited by 4
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure
Yokota, T., Koiwa, H., Matsushima, S., Tsujinaga, S., Naya, M., Morisaki, H., & Morisaki, T. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.11.010 · Cited by 4
Ring, N., Volpe, M. C., Stepišnik, T., Mamolo, M. G., Panov, P., Kocev, D., Vodret, S., Fortuna, S., Calabretti, A., Rehman, M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04439-4 · Cited by 4
“A major inducer of myofibroblast activation is transforming growth factor β (TGFβ) [4], which increases the secretion of extracellular matrix components, and the expression of the contractile protein alpha-smooth muscle actin (αSMA), currently considered to be the most reliable marker of this cell type [5].”
BackgroundZhang, J., Cao, L., Wang, W., Huo, Y., Zheng, Y., Wu, F., & Gui, Y. (2022) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174422000095 · Cited by 5
Zhang, Y., Wang, D., Wu, K., Shao, X., Diao, H., Wang, Z., Sun, M., Huang, X., Li, Y., Tang, X., et al. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/5642307 · Cited by 4
“TGFβ1-Smad2/3 signaling participates in the progression of cardiac fibrosis and is considered a classical pathway in regulating cardiac fibrosis [21].”
BackgroundLi, C., Zhang, Z., Yu, P., Zhang, Y., Kang, W., Li, Y., & Yang, H. Y. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11340 · Cited by 4
“Previous studies have indicated that Smad3 is a critical mediator of myofibroblast differentiation in vitro and is the dominant effector of cardiac fibrosis in vivo , but Smad2 is not necessary for this response (23,24).”
Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline
Tamargo, J. L., Tamargo, M., & Caballero, R. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2113374 · Cited by 5
“TGF-β ● Activation of the TGF-β-Smad2/3 signaling pathway in cardiac myocytes and fibroblasts leads to fibrosis and hypertrophy, diastolic dysfunction and HF [144,188] ● Therapeutic approaches: TGF-β receptor blocking antibodies [189], deletion of Smad2/3 or Tgfbr1/2 from cardiac fibroblasts to inhibit extracellular m…”
BackgroundA Scoping Review on COVID-19-Induced Cardiovascular Complications
Osoro, I., Vohra, M., Amir, M., Kumar, P., & Sharma, A. (2023) · COVID · doi:10.3390/covid3030026 · Cited by 4
Novel role for cardiac myocyte-derived β-2 microglobulin in mediating cardiac fibrosis
Boyer, M. J., & Eguchi, S. (2018) · Clinical Science · doi:10.1042/cs20180681 · Cited by 4
Garvin, A. M., Floyd, D. B., Bailey, A. C., Lindsey, M. L., Carroll, C. C., & Hale, T. M. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00753.2024 · Cited by 3
SNAI2 , a potential crossing point between cancer and cardiovascular disease
Liu, Z., Wang, Y., Li, L., Liu, L., Li, Y., Li, Z., Xie, Y., & Yu, F. (2025) · The FASEB Journal · doi:10.1096/fj.202500198r · Cited by 3
“140,141 AMPK is a key regulator of metabolism in most cells and can control cell growth and several other cellular processes, including lipid and glucose metabolism and auto-phagy, by sensing low cellular ATP levels.”
Kraus, L., Fredericks, S., & Scheeler, K. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1539826 · Cited by 4
Ge, H., Du, Z., Liu, W., Wang, L., Li, J., Yang, G., & Li, A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1578877 · Cited by 3
Plavelil, N., Goldstein, R. E., Klein, M. G., Michaelson, L. P., Haigney, M. C., & Hood, M. N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136088 · Cited by 3
“TGF-β 1 binds to the TGF-β 1 receptors, activates Smad2/3 cascade, and induces the transformation of myofibroblast to fibroblasts [8].”
Soluble T-cadherin ameliorates pressure overload-induced heart failure and cardiac fibrosis in mice
Kondo, Y., Fukuda, S., Kawada, K., Kita, S., Nakamura, Y., Nagao, H., Obata, Y., Fujishima, Y., Maeda, N., Nishizawa, H., et al. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152459 · Cited by 3
Tavares, A. H., Connelly, S. P., Maksat, D., Zheng, J., Rabhi, N., & Layne, M. D. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110563 · Cited by 5
“Genes regulated by the SMAD2/3 axis of the TGF-β 1 signaling cascade are closely associated with tissue remodeling and fibrosis (15, 16).”
Gu, H., Yang, T., Qin, Z., Zhang, S., Wang, L., & Zhao, Z. (2025) · BMC Urology · doi:10.1186/s12894-025-01892-7 · Cited by 3
“The upregulation of α-SMA and Collagen I in our models confirms the presence of activated myofibroblasts, which are responsible for excessive extracellular matrix deposition and subsequent tissue rigidity and stricture formation [17, 18].”
Liu, C., Yuan, J., Cheng, P., Yang, T., Liu, Q., Li, T., Li, C., Qu, H., & Zhou, H. (2025) · Pharmaceuticals · doi:10.3390/ph18091317 · Cited by 3
“Deletion of TGF-β receptors and Smad2/3 has been shown to suppress fibrosis and ECM remodeling gene programs [104].”
Akins, K. A., Arkatkar, A., Flinn, M. A., Sandor, N., Purdy, A. L., Brusacoram, A., Swift, S. K., Buday, S. L., Choudhury, P., Cui, M., et al. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101455 · Cited by 6
Nanoparticle-mediated cardiotoxicity and nanomedicine interventions in cancer treatment
Oisakede, E. O., Oyedeji, O. O., Olawuyi, O. F., Alabi, J. O., Daniel, R. I. A., & Olawade, D. B. (2026) · Nano TransMed · doi:10.1016/j.ntm.2026.100113 · Cited by 4
Composition and Influence of Fibrogenic Niche in Myocardial Fibrosis
Wang, X., Fan, L., Yuan, Q., Luo, Y., Cheng, Z., Chen, Y., & Gong, C. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44112 · Cited by 3
“For example, TGF-β -Smad2/3 signaling underlies cardiac fibrosis [48].”
Metadata
- Authors
- Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., Karch, J., & Molkentin, J. D.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- Johns Hopkins University (US)
- Corresponding author
- Molkentin, Jeffery D.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-09-11
- Volume
- 127
- Issue
- 10
- Pages
- 3770-3783
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5617658
- OpenAlex
- W2750808153
- Cited by
- 905
- References
- 64
- Citations by year
- 2026: 92 · 2025: 102 · 2024: 128 · 2023: 121 · 2022: 144 · 2021: 110 · 2020: 84 · 2019: 85 · 2018: 34 · 2017: 2
- FWCI
- 43.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Civil War Book Review (submittedVersion)
- Language arts journal of Michigan (submittedVersion)
- Funders
- National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (158486, 148429)
- National Institutes of Health
- National Heart, Lung, and Blood Institute (P01HL069779, R01HL105924)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR060636)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- myocardial fibrosis, TGF-beta signaling, Smad2, Smad3, cardiac fibroblasts, myofibroblasts, TGF-beta receptor, pressure overload, cardiac hypertrophy, extracellular matrix remodeling
- MeSH terms
- Receptor, Transforming Growth Factor-beta Type I, Receptor, Transforming Growth Factor-beta Type II, Animals, Fibrosis, Heart Diseases, Male, Mice, Transgenic, Myocardium, Organ Specificity, Signal Transduction, Transforming Growth Factor beta, Protein Serine-Threonine Kinases, Gene Deletion, Receptors, Transforming Growth Factor beta, Myocytes, Cardiac, Mice, Smad2 Protein, Smad3 Protein, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.